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AbstrAct
Objectives To assess the time from symptom onset 
to treatment for neovascular age-related macular 
degeneration (nvAMD) and to measure the awareness of 
AMD in Southeast Scotland.
Design Retrospective cross-sectional study.
setting Secondary care, Southeast of Scotland.
Methods Patients treated with intravitreal therapy (IVT) 
for nvAMD in Southeast Scotland between 2013 and 2015 
were identified using a treatment register. Notes were 
retrospectively reviewed. We measured time from:  
(A) symptom onset to first presentation at primary care,  
(B) referral to ophthalmic clinic appointment and (C) 
ophthalmic clinic appointment to first IVT treatment. To 
investigate AMD awareness, we performed a cluster random 
sample survey of patients visiting non-AMD ophthalmic clinics 
using a previously validated 12-item questionnaire.
results 195 patients (mean age 78 years) were included in 
the study. The mean delays between the different stages—A, 
B and C—were 54.2 (95% CI ±13), 28.2 (95% CI ±4.0) and 
31.5 (95% CI ±3.6) days, respectively. There was an additional 
mean delay of 7.5 (95% CI ±1.6) days when patients were 
indirectly referred by optometrists via general practitioners 
(P<0.05). 140 patients (mean age 78) participated in the 
awareness survey; 62.1% reported being ‘aware’ of AMD but 
only 37.3% described AMD symptoms correctly.
conclusions There was a significant delay at every step 
of the nvAMD care pathway. The causes for this were 
multifactorial and included delays in first presentation to a 
healthcare provider, referral from primary care and initiation of 
secondary care treatment. Our data are likely to underestimate 
prehospital delays as a large number of cases are likely to 
have undefined symptoms and onset. We also identified 
suboptimal awareness of AMD which could account for a 
substantial delay in presentation from symptom onset. These 
findings highlight the need to address AMD awareness and 
the need for urgent treatment to prevent avoidable vision loss 
resulting from nvAMD.
IntrODuctIOn
Age-related macular degeneration (AMD) is 
the leading cause of vision loss in the devel-
oped world.1 There are two main forms of 
AMD. The first is non-neovascular (dry) AMD 
which accounts for the majority of AMD cases 
and results from the deposition of drusen 
(small yellow or white deposits) underneath 
the retina that eventually leads to the slow 
degeneration of retinal cells resulting in 
blindness. Neovascular (wet) AMD (nvAMD) 
accounts for the remaining cases of AMD 
and results from the development of new 
blood vessels deep to the retina which leak 
or bleed resulting in symptoms of new distor-
tion or vision loss. nvAMD results in irrevers-
ible blindness if left untreated and accounts 
for 90% of the cases of blind registration 
resulting from AMD.2 The main risk factors 
associated with AMD are age and smoking.3 
Cases of blindness resulting from AMD are 
predicted to increase together with an ageing 
population.4 
An effective treatment is currently available 
to preserve vision in nvAMD in the form of 
intravitreal therapy (IVT) with antivascular 
endothelial growth factor agents.5–8 These 
drugs have been shown to be effective in 
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Research
strengths and limitations of this study
 ► Case notes of consecutive patients identified 
systematically using a treatment clinic register over 
2 years.
 ► Demographic factors such as age, gender, 
education, social class and smoking status were 
taken into account for analyses of age-related 
macular degeneration (AMD) awareness.
 ► Unable to ascertain direct association between 
low disease awareness and delay in treatment for 
patients with neovascular AMD as different cohort of 
patients were examined.
 ► Due to retrospective analysis of notes from a 
disease register in this study, the number of patients 
who could be included was limited by the quality of 
note-keeping.
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Figure 1 Flow chart depicting the typical care pathway of a patient with neovascular age-related macular degeneration (AMD) 
in Southeast Scotland. *Based on the recommendations by the Royal College of Ophthalmologists in its 2013 AMD guideline.14
maintaining long-term vision in the majority of patients 
affected by nvAMD.9 Delay in instituting IVT treatment 
in new cases of nvAMD has been shown to be one of the 
most important factors negatively impacting final visual 
outcome.10 11 Consequently, the early diagnosis and treat-
ment is crucial to improving visual outcomes in AMD and 
to reduce the social and economic burden of blindness 
resulting from the disease.12 13
Delays from symptom onset to treatment can be expe-
rienced at different stages of the patient care pathway 
for new onset nvAMD. These include: (1) time of first 
symptom onset to presentation at primary care practi-
tioner, (2) time from primary care referral to presentation 
at ophthalmic clinic and (3) time from ophthalmic clinic 
to first IVT treatment (figure 1).14 These early stages of 
the care pathway also represent the periods during which 
lesions may be most active and amenable to the benefits 
of therapy.15
There have been many published reports investigating 
intrahospital factors such as the time from first ophthalmic 
clinic visit to first IVT treatment.10 11 16 However, there is 
a scarcity of literature reporting the extrahospital factors 
such as the time from symptom onset to presentation at 
ophthalmic clinic. In addition, despite its significance in 
causing blindness, limited research has been performed 
to investigate AMD awareness. An exploration of patient’s 
awareness and knowledge of disease has been demon-
strated in other chronic diseases such as stroke and 
cancer,17 18 with increased awareness associated with 
improved patient outcomes.19 20
The primary objectives of this study were twofold: first, 
to assess the time between the different stages of the 
nvAMD care pathway in patients treated in Southeast 
Scotland and second, to evaluate patients’ awareness of 
AMD, its risk factors and treatment options.
MethODs
Case notes of consecutive patients diagnosed and treated 
with IVT for nvAMD in NHS Lothian since September 
2013 were identified using a treatment clinic register. 
A 2013 cut-off point was chosen to reflect the updated 
guidelines on AMD by the Royal College of Ophthalmolo-
gists (RCOphth) which were published at the time.14 The 
guidelines recommended that all patients with suspected 
AMD should be seen by a retinal specialist within 1 week 
of referral and that treatment should commence within 
1 week of first ophthalmic appointment (figure 1).
In this study, the main outcome measures were: (1) time 
from symptom onset to first presentation at primary care 
(ie, duration of visual symptoms before initial presenta-
tion), (2) time from primary care referral to ophthalmic 
clinic appointment and (3) time from ophthalmic clinic 
appointment to first IVT treatment. The main exclu-
sion criteria were case notes with incomplete data and 
the coexistence of ocular comorbidities that gave rise to 
choroidal neovascularisation. This study was approved 
as part of a wider service evaluation which was accepted 
following review by the NHS Lothian Ophthalmology 
Quality Improvement Team on 8 October 2015.
In order to investigate patients’ awareness of AMD, a 
cluster random sample of patients visiting ophthalmic 
clinics for non-AMD disease in NHS Lothian was surveyed 
using a 12-item questionnaire (see online supplementary 
file 1). The sample size required for the study was calcu-
lated using a power calculation (see online supplementary 
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Figure 2 Breakdown of the total delay (121.4 days) from symptom onset to treatment for patients with new neovascular age-
related macular degeneration in Southeast Scotland. GP, general practitioner.
file 2). Questions were adapted from a previously vali-
dated questionnaire21 and served to ascertain each 
patient’s knowledge of AMD and its risk factors. Patients 
were asked for their demographic details, including age, 
sex, education and postal code of residence. Socioeco-
nomic deprivation scores (social class) were calculated 
for all patients from postal code data at the time of inter-
view using the Scottish Index of Multiple Deprivation 
(SIMD).22 The SIMD combines weighted data on seven 
domains (income, employment, education, housing, 
health, crime and geographical access) and is officially 
sanctioned by the Scottish Government as a measure of 
multiple deprivation.23 24
The first part of the questionnaire explored patients’ 
familiarity with AMD and its risk factors. The second 
part enquired about patients’ smoking status and their 
awareness of available treatments for AMD. Surveys were 
distributed and collected by the same researcher, who 
remained nearby to answer any questions about instruc-
tions. No additional assistance was provided. The survey 
was performed from 18 November 2015 to 31 November 
2015 and data were analysed using Pearson χ2 tests except 
for education and social class where χ2 tests for trend were 
performed. Data analysis was done using IBM SPSS Statis-
tics for Windows, V.23 (IBM, Armonk, New York, USA).
results
Delay in presentation, referral and treatment of AMD in 
southeast scotland
A total of 315 case notes were identified; 120 of the 315 
were excluded after application of the exclusion criteria 
(see online supplementary data for the demographics 
and breakdown of excluded cases), leaving 195 case notes 
for analysis. One hundred and twenty (61.5%) patients 
were women, with a mean age of 78 years. Nearly all 
patients (187; 95.9%) presented with nvAMD affecting 
the first eye. The overall mean time from symptom onset 
to presentation was 54.2 (95% CI ±13) days. As for refer-
rals to ophthalmology, 118 (60.5%) of these were direct 
from optometrists, 5 (2.6%) were direct from general 
practitioners (GPs) and 52 (26.7%) were made by optom-
etrists via GPs. The remaining referrals were from other 
hospitals, other ophthalmology clinics and screening 
programmes.
The mean time from referral to ophthalmic clinic 
appointment was 28.2 days (95% CI ±4.0 days). There was 
a significant additional mean delay of 7.5 (P<0.05) (95% 
CI ±1.6) days when patients were referred from their 
optometrist via their GP. During clinic appointments, 
fundus fluorescein angiogram was performed in approx-
imately one-third of patients (66/195). The mean time 
from clinic to first IVT treatment was 31.5 (95% CI ±3.6) 
days (figure 2).
Awareness of AMD and its risk factors
The delay from symptom onset to first injection resulted 
from both intrahospital and extrahospital factors. We 
have already identified that when optometrists referred 
via the GPs instead of directly to the hospital eye service 
this resulted in a significant increased delay. However, 
even this delay is overshadowed by the mean delay from 
symptom onset to presentation at primary care service. 
In order to better understand patient factors that may 
have resulted in this delay in presentation we performed 
a questionnaire survey on patients with unrelated disease 
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Table 1 Demographic data of patients (N=140)
Variable n %
Gender
  Male 61 43.6
  Female 79 56.4
Age (years)
  <50 19 13.6
  ≥50 121 86.4
Highest education level attained
  Primary school 4 2.9
  Secondary school 78 55.7
  College 31 22.1
  University degree 27 19.3
Social class
  I 13 9.3
  II 25 17.8
  III 20 14.3
  IV 27 19.3
  V 55 39.3
Smoking status
  Current smoker 11 7.9
  Ex-smoker or non-smoker 129 92.1
Table 2 Respondents indicating awareness of AMD 
(N=140)
Characteristic*
No of respondents 
indicating awareness/
total no (%)
Gender distribution
  Male 31/61 (50.8)
  Female 56/79 (70.9)
  P value 0.015 
Age (years)
  <50 8/19 (42.1) 
  ≥50 79/121 (65.3) 
  P value 0.053 
Highest education level attained
  Primary school 4/7 (57.1) 
  Secondary school 37/75 (49.3) 
  College 23/31 (74.2) 
  University degree 23/27 (85.2) 
  P value† 0.001 
Social class
  I 8/13 (61.5) 
  II 18/25 (72.0) 
  III 9/20 (45.0) 
  IV 21/27 (77.8) 
  V 31/55 (56.4) 
  P value† 0.537 
Smoking status
  Current smoker 6/11 (54.5) 
  Ex-smoker or non-smoker 81/129 (62.8) 
  P value 0.588 
*Unless otherwise indicated, P values are derived using the 
Pearson χ2 test.
†Derived using the χ2 for trend.
in the eye service. A total of 142 patients were approached 
in non-AMD ophthalmic clinics. These clinics included 
glaucoma, ocular motility and general outpatient clinics. 
One hundred and forty patients agreed to participate. 
Two refused because of unwillingness and inability to 
understand the purpose of the questionnaire due to deaf-
ness respectively.
The cohort included 61 (43.6%) men and 79 (56.4%) 
women with a median age of 73 (range: 17–93) years, 
comprising all social classes. The education level of 
patients ranged from primary education to university 
degree. Details of the demographic data are given in 
table 1.
Of the 140 respondents, 87 (62.1%) reported being 
‘aware’ of AMD. Fourteen (10%) had previously been 
diagnosed with AMD. Out of these 14 patients (71.4%), 
10 were able to provide a correct description of the 
symptoms of AMD. For those patients without a prior 
diagnosis, only 47/126 (37.3%) were able to correctly 
report the symptoms of AMD. There was a significant 
difference when comparing the responses of those who 
had a previous diagnosis of AMD to those without AMD 
(P=0.013). Overall, female respondents were more likely 
than male respondents to report awareness of AMD 
(P=0.015) (table 2). Increased awareness of AMD was also 
seen with higher levels of education (P=0.001).
The top risk factor for AMD correctly considered by 
patients was age (127/140–90.7%). The other risk factors 
identified included smoking in 82 (58.6%), unprotected 
UV exposure in 62 (44.3%), genetic predisposition in 62 
(44.3%), vitamin deficiency in 54 (38.6%) and gender in 
15 (10.7%).
Eighty-seven (62.1%) of patients thought that AMD 
was a treatable condition. However, only 20/87 (23%) 
were able to provide correct information on the avail-
able treatments (ie, eye injections and laser therapy). 
The majority of patients (91/140, 65%) considered opti-
cians to be their first port of call if they had vision prob-
lems. Other healthcare professionals cited as first port of 
call included GPs in 28 (20%) and ophthalmologists in 
21 (15%).
DIscussIOn
The RCOphth has recently updated its guidance on 
suggested waiting times for IVT treatment in nvAMD 
in the hospital setting. It recommends that all patients 
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should be seen by a retinal specialist within 1 week 
of primary care referral, and should begin treatment 
within 1 week following this.14 The new guidelines place 
increased importance on correct diagnosis and urgent 
referral from primary care and place increasing emphasis 
on hospital eye services to provide capacity for urgent 
new AMD cases in addition to the treatment of existing 
patients with nvAMD. However, this study finds that there 
are significant delays at each step of the nvAMD care 
pathway in south-east Scotland; both the waiting times 
from: (1) primary care referral to ophthalmic clinic and 
(2) initial ophthalmic assessment to treatment are about 
four times as long as the recommended gold standard. In 
addition, there is a further 1-week delay on average when 
indirect referrals are made by optometrists via GP. Similar 
findings have also been reported in previous studies 
which have demonstrated similar, if not longer, delays for 
intrahospital pathways (ie, from initial ophthalmic assess-
ment to treatment).10 11 16
Delays from intrahospital pathways may be attributed 
to the inherent diagnostic and referral pathways within 
different healthcare systems. In Southeast Scotland, a 
new IT scheme linking community optometrists and eye 
clinics within hospitals across all of Scotland was intro-
duced in 2010 following a successful pilot scheme in NHS 
Fife which allowed optometrists to make direct electronic 
referrals to ophthalmologists.25 However, the system has 
yet to be fully integrated into all units. Our study has 
highlighted that there is still much room for improve-
ment for both the primary care referral system, and also 
within the acute referral clinics themselves. The current 
electronic system still relies on a manual, ad hoc system 
for making referrals. An important step forward would be 
to develop a semiautomated referral system so that eye 
care providers can track patient referrals, obtain data on 
patient leakages and receive automatic notifications when 
there is lack of follow-up.
To our knowledge, this is the first study to evaluate 
the time from symptom onset to presentation at clinic 
(extrahospital pathway) for patients with nvAMD in the 
UK. There are, however, several limitations to the study. 
First, assessment of presentation delay might be difficult 
due to the retrospective nature of evaluation of symptom 
onset by patients. Second, the perception of symptoms is 
also highly subjective, often depending on factors such 
as existing cognitive function, ocular dominance of the 
affected eye and baseline visual acuity of the unaffected 
eye. Nevertheless, it is noteworthy that this time interval 
often varies widely between patients and is prolonged in 
most cases. Therefore, although less accurate than formal 
angiographic diagnosis, we thought it is important to 
investigate this time interval as it would be accessible to 
intervention.
Our findings demonstrate that presentation delay 
represents a major source of delay and accounts for 
the greatest proportion of the delay in the nvAMD 
care pathway in Southeast Scotland. This represents an 
important target for improvement to reduce vision loss 
resulting from delay in the nvAMD care pathway.26 This 
delay is likely to be complex and multifactorial, involving 
patients, eye care providers and healthcare systems. 
Barriers to early presentation might include a lack of 
awareness of AMD among patients, self-examination 
by patients and screening of the disease by non-retina 
specialists. This can be further compounded by issues 
such as transport difficulties, age-related infirmity and 
a mismatch between patient expectations on speed of 
referral and recommended guidelines.27 Further studies 
are warranted into the reasons underlying our findings 
in both primary care and hospital eye service environ-
ments in order that appropriate measures are taken 
to identify patients early and build service capacity 
accordingly.
At present, the diagnosis of new nvAMD, especially for 
the first affected eye, still very much relies on self-recog-
nition of visual symptoms by patient themselves. This is, 
however, problematic as those affected in only one eye 
tend not to be aware of the visual change and may there-
fore remain ‘asymptomatic’ for a considerable length 
of time.28 Indeed, this seemed to be case in our study in 
which nearly all patients presented with nvAMD affecting 
the first eye.
There is evidence to show that the best-corrected visual 
acuity at the time of diagnosis of nvAMD is worse for the 
first affected eye when compared with that of the second 
eye.29 In addition, previous studies have shown that the 
visual prognosis of the first affected eye following 1 year 
of treatment is usually worse compared with that of the 
second affected eye in nvAMD.30 31 These better outcomes 
of the second affected eye are most likely due to increased 
awareness and more frequent monitoring of the second 
eye as part of a systematic bilateral follow-up examina-
tion for the first affected eye. These factors would seem-
ingly translate into a shorter delay in presentation for 
the second affected eye, but it should be noted that this 
association was not explored in our study and remains to 
be investigated. Nonetheless, the considerable delay in 
presentation for the first affected eye demonstrated in 
our study highlights the importance of early detection 
and treatment.
From the patient’s perspective, the delay in symptom 
recognition can be addressed to a certain extent by 
self-examination. Patients, especially those with an 
increased risk of developing nvAMD, should be educated 
and made aware of symptoms such as new visual distor-
tion and sudden reduction in vision. This can be achieved 
by encouraging patients to use suitable spaced self-tests of 
vision which examine one eye at a time to prevent compen-
sation from the good eye. The standard Amsler test has 
long been recommended as the standard self-monitoring 
test, but there has been increasing reservation about its 
utility as a diagnostic tool due to its insufficient reliability 
and variable sensitivity.32 33 The advent of more innova-
tive, cost-saving technologies may circumvent these issues 
and make implementation of self-examination on a wider 
public scale more feasible in the near future.34 35
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In this study, we chose to investigate patients’ awareness 
of AMD because it is clear that a lack of disease aware-
ness is a common factor for delayed presentation in other 
eye conditions such as glaucoma, retinal detachment and 
central retinal artery occlusion.36 37 The only previous 
study to investigate AMD awareness in the UK popula-
tion showed a low awareness (16%).38 Our study adds 
to the existing literature by demonstrating that public 
awareness of AMD is still limited. Our survey shows that 
awareness of AMD is unacceptably low (37%), especially 
considering that this condition is the leading cause of 
blindness in developed countries.1 The low awareness of 
AMD is also consistent with the low levels of awareness 
of AMD in other countries including Australia, Hong 
Kong, Singapore, Nepal, Bangladesh, China and the USA 
(range between 5% and 50.5%).21 38–44 It is likely that our 
findings underestimate the true scale of lack of aware-
ness among the general population because we sampled 
ophthalmic patients who, by virtue of being surveyed in 
an eye hospital, are presumably somewhat more attuned 
to common eye diseases. Our survey also highlights a 
low awareness of risk factors of AMD (other than age). 
However, this assessment could be limited by the lack of 
plausible distractors in the corresponding question which 
might have increased the respondent’s chances of getting 
a correct answer(s), hence again underestimating the 
true scale of lack of awareness.
These findings are important given the severity of the 
consequences of delayed presentation in AMD and the 
ready availability of an effective treatment to prevent 
visual loss. We identified AMD-naive male patients and 
those with lower education levels to have a particularly 
low awareness of warning symptoms of AMD, suggesting 
the need for targeted intervention for these subgroups. 
As increased awareness can lead patients to seek appro-
priate medical care, improving awareness would logically 
lead to better visual prognoses for patients.
There is currently still a need for a unified national 
awareness campaign on AMD in the UK. A recent report 
by the Royal National Institute of Blind People highlighted 
that most initiatives at improving AMD awareness in the UK 
still operate at a local level.27 Even then, these efforts often 
comprised of educational talks targeted at existing patients, 
rather than raising public awareness. The need for a 
national campaign has also been recognised by the Macular 
Society which has made increasing AMD awareness one of 
the main objectives of its 5-year national strategy.45
Although some progress has been made since,46 there is 
still room for improvement. Current awareness interven-
tions need to be further optimised for a sustained impact. 
A promising step would be the adoption of the multilay-
ered approach as adopted by other developed countries.47 
This approach saw the use of a campaign which included 
a diverse range of activities such as promoting education 
programmes for patients and primary care, running a 
national advertising campaign and providing free mobile 
screening. The end of this focused campaign saw a 
dramatic increase in AMD awareness and the number of the 
population requesting fundus examination for symptoms 
of AMD.47 The implementation of a similar public health 
strategy in the UK may achieve similar desirable effects, but 
further research is needed to evaluate the effectiveness of 
this approach in the UK population. Another important 
gap highlighted by our study is the underappreciated link 
between smoking and AMD. This represents a potent novel 
health promotional tool and awareness could be increased 
by incorporating information in existing campaigns with 
other smoking-related diseases.48 49
Lack of awareness and knowledge of correct referral 
among non-ophthalmologists is also problematic. This 
may account for the delay in referral demonstrated in our 
study. A recent national survey revealed that 32% of GPs felt 
‘deskilled’ in diagnosing common eye conditions.50 The 
same survey also showed that 38% of GPs felt that eyes are 
the most difficult part of the body to diagnose. Achieving a 
better alignment of ophthalmic knowledge between health-
care organisations and professionals will help improve 
understanding and management of common ophthalmic 
disorders for those in the front line of eye care.
cOnclusIOn
There is significant delay at every step of the care pathway 
for patients with nvAMD in Southeast Scotland. We also 
show that awareness and knowledge of AMD are subop-
timal. This lack of AMD awareness could account for the 
long presentation delay of AMD to primary care. This 
suggests that efforts to educate the public regarding AMD 
may lead to earlier presentation and hence improved 
visual outcomes in patients.
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